206 related articles for article (PubMed ID: 2939797)
21. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
[TBL] [Abstract][Full Text] [Related]
22. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Hyatt JM; Nix DE; Stratton CW; Schentag JJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
[TBL] [Abstract][Full Text] [Related]
23. Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Ansorg R; Müller KD; Wiora J
Chemotherapy; 1990; 36(3):222-9. PubMed ID: 2110878
[TBL] [Abstract][Full Text] [Related]
24. Basis for nebulized antibiotics: droplet characterization and in vitro antimicrobial activity versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
Todisco T; Eslami A; Baglioni S; Sposini T; Tascini C; Sommer E; Knoch M
J Aerosol Med; 2000; 13(1):11-6. PubMed ID: 10947319
[TBL] [Abstract][Full Text] [Related]
25. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.
Zinner SH; Klastersky J; Gaya H; Bernard C; Ryff JC
Antimicrob Agents Chemother; 1981 Oct; 20(4):463-9. PubMed ID: 6282192
[TBL] [Abstract][Full Text] [Related]
27. [Study of quinolones resistance in Escherichia coli, Staphylococcus aureus and Pseudomonas areuginosa].
Feng P; Yu R; Xia P; Lü X; Zhu S
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):501-4. PubMed ID: 12528531
[TBL] [Abstract][Full Text] [Related]
28. Pseudomonas aeruginosa: in vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated human blood.
Traub WH; Spohr M; Bauer D
Chemotherapy; 1988; 34(4):284-97. PubMed ID: 3145172
[TBL] [Abstract][Full Text] [Related]
29. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
30. [Influence of human albumin on bactericidal or antibacterial activities of cephems and monobactams].
Saionji K
Jpn J Antibiot; 1988 Oct; 41(10):1390-406. PubMed ID: 3144613
[TBL] [Abstract][Full Text] [Related]
31. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
[TBL] [Abstract][Full Text] [Related]
32. Effect of azlocillin and piperacillin in subinhibitory and inhibitory concentrations on Staphylococcus aureus and Pseudomonas aeruginosa in broth, in serum and in the presence of human polymorphonuclear leukocytes.
Bassler M; Depuis W; Utz E; Just HM; Daschner FD
Eur J Clin Microbiol; 1983 Oct; 2(5):439-44. PubMed ID: 6416838
[TBL] [Abstract][Full Text] [Related]
33. Hyperoxia and the antimicrobial susceptibility of Escherichia coli and Pseudomonas aeruginosa.
Muhvich KH; Park MK; Myers RA; Marzella L
Antimicrob Agents Chemother; 1989 Sep; 33(9):1526-30. PubMed ID: 2510593
[TBL] [Abstract][Full Text] [Related]
34. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of ciprofloxacin combined with azlocillin.
Moody JA; Peterson LR; Gerding DN
Antimicrob Agents Chemother; 1985 Dec; 28(6):849-50. PubMed ID: 2935078
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal beta-lactam agents against clinical isolates of Pseudomonas aeruginosa.
Stratton CW; Franke JJ; Weeks LS; Manion FA
Diagn Microbiol Infect Dis; 1988 Sep; 11(1):41-52. PubMed ID: 3146458
[TBL] [Abstract][Full Text] [Related]
37. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
Allocati N; Catamo G; Cellini L
Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
[TBL] [Abstract][Full Text] [Related]
38. In vitro studies of synergistic interaction between aztreonam and cefoperazone.
Borowski J; Zaremba M; Feliński J
Chemioterapia; 1987 Jun; 6(2 Suppl):109-10. PubMed ID: 3151329
[No Abstract] [Full Text] [Related]
39. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
Hyatt JM; Nix DE; Schentag JJ
Antimicrob Agents Chemother; 1994 Dec; 38(12):2730-7. PubMed ID: 7695254
[TBL] [Abstract][Full Text] [Related]
40. Different patterns of bacterial DNA synthesis during postantibiotic effect.
Gottfredsson M; Erlendsdóttir H; Gudmundsson A; Gudmundsson S
Antimicrob Agents Chemother; 1995 Jun; 39(6):1314-9. PubMed ID: 7574522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
